研究单位：[1]Chengdu Kanghong Biotech Co.,Ltd.[2]Peking Union Medical College Hospital Beijing,China[3]Peking University Third Hospital Beijing,China[4]The 306Th Hospital of Pla Beijing,China[5]Xuanwu Hospital Capital Medical University Beijing,China[6]Sichuan Provincial People's Hospital Chengdu,China[7]The Second Affiliated Hospital of Chongqing Medical University Chongqing,China[8]The First Affiliated Hospital of Dalian Medical University Dalian,China[9]The Second Affiliated Hospital of Guangzhou Medical University Guangzhou,China
研究目的：
This is a post-marketing drug safety monitoring study in a prospective manner, and data collection will be performed in a registration-follow-up manner. Safety information about patients who have received intravitreal injection of Conbercept Ophthalmic Injection in medical institutions involved in the study during research will be actively monitored without intervening in diagnosis and treatment. All patients enrolled will be followed up for one year.
